Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
background treatment · 1 trial · 8 indications
Pathological response will be assessed considering all removed breast and lymphatic tissues from all surgeries. Surgery takes place shortly after the 18 weeks (six 3-week cycles) chemotherapy treatment. No microscopic evidence of residual viable tumor cells in all resected specimens of the breast and axilla meets the primary endpoint.
| Arm | Type | Description |
|---|---|---|
| Carboplatin + background treatment | EXPERIMENTAL | Carboplatin AUC 2 min/mL weekly, infusion will be used as Add-on to the background therapy (same as comparator arm) |
| background treatment only | ACTIVE_COMPARATOR | background treatment with NLPD (Myocet), Paclitaxel, Herceptin (Trastuzumab fpr Her2 pos), Tyverb (Lapatinib for Her2 pos), Avastin (Bevacizumab for triple negative) agents are used according to marketed formulation via normal procedures at each site and applied according to recommendations of the manufacturers. |
| Name | Type | Description |
|---|---|---|
| Carboplatin | DRUG | Carboplatin, AUC, 2 min/mL weekly, infusion |
| background treatment | DRUG | background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg. Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients). |
Inclusion Criteria: * 1.Written informed consent for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures. * 2.Complete baseline documentation must be submitted via Medcodes® and approved by GBG Forschungs GmbH. * 3.Unilateral or bilateral ...
The background treatment is a small molecule being studied for use in oncology, specifically in patients with tubular breast cancer stage II. It is part of a neoadjuvant therapy regimen for early breast cancer, including triple-negative and HER2-positive subtypes.
The background treatment is being developed by Teva Pharmaceutical Industries Limited, a company traded on the NYSE under the ticker TEVA. The drug is currently in Phase 2 clinical development.
The background treatment is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
The background treatment was studied in clinical trial NCT01426880, titled "Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer." This Phase 2 trial enrolled 595 female participants aged 18 years and older in Germany.
The background treatment is not the same as carboplatin. In the clinical trial NCT01426880, carboplatin was added to the background treatment as part of the neoadjuvant therapy regimen. The background treatment serves as the standard backbone to which carboplatin was added.